Sequential, cycling maintenance therapy for post transplant multiple myeloma

Bone Marrow Transplantation

Volumn 37, Issue 1, 2006, Pages 89-94

  Chen, Christine I ^a   Nanji, S ^a   Prabhu, A ^a   Beheshti, R ^a   Yi, Q L ^a   Sutton, D ^b   Stewart, A K ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c McLaughlin Centre for Molecular Medicine   (Canada)

Author keywords

Alkylating agents; Glucocorticosteroids; Interferon; Maintenance theraphy; Multiple myeloma; Stem cell transplant

Indexed keywords

ALPHA INTERFERON; ANTIDIABETIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE ATROPHY; BRONCHITIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; FOOT DISEASE; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INSOMNIA; LEUKEMIA; LIBIDO DISORDER; MAINTENANCE THERAPY; MALE; METASTASIS; MOOD DISORDER; MULTIPLE MYELOMA; MYELODYSPLASIA; NEUTROPENIA; OSTEOPENIA; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SEXUAL DYSFUNCTION; SKIN DISEASE; SKIN TINGLING; SURVIVAL TIME; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; MALE; MELPHALAN; MULTIPLE MYELOMA; PILOT PROJECTS; PREDNISONE; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 31344432649     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705206     Document Type: Article

References (26)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
2. Wisloff F, Eika S, Hippek E, Hjorth M, Holmberg E, Kaasa S et al. Measurement of health-related quality of life in multiple myeloma. Br J Haematol 1996; 92: 604-613.
3. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457-481.
4. Gulbrandsen N, Hjermstad MJ, Wisloff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004; 72: 172-180.
5. Belch A, Shelley W, Bergasagel D, Wilson K, Klimo P, White D et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94-99.
6. Peest D, Deicher H, Coldewey R, Schmoll H, Schedel I. Induction and maintenance therapy in multiple myeloma: A multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 1988; 24 (6): 1061-1067.
7. Casciato D, Scott J. Acute leukemia following prolonged cytotoxic agent therapy. Medicine 1979; 58: 32-47.
8. Leone G, Voso M, Sica S, Morosetti R, Pagano L. Therapy related leukemias: Susceptibility, prevention and treatment. Leuk Lymphoma 2001; 41: 255-276.
9. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Haematol 1998; 102: 495-502.
10. 2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: Results of Intergroup Trial S9321. Blood 2003; 102: 42A.
11. The Myeloma Triallist's Collaborative Group. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020-1034.
12. Mahendra P, Hood I, Johnson D, Ethell M, Jestice H, Scott M et al. Autografting for multiple myeloma: A 5-year experience at a single institution. Bone Marrow Transplant 1995; 16: 759-763.
13. Bensinger W, Rowley S, Demirer T, Lilleby K, Schiffman K, Clift R et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-1456.
14. Barlogie B, Jagannath S, Desikan K, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
15. Dimopoulos M, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S et al. Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow of blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324-2328.
16. Alegre A, Diaz-Mediavilla J, San-Miguel J, Martinez R, Larana J, Sureda A et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry. Bone Marrow Transplant 1998; 21: 133-140.
17. Salmon S, Crowley J, Balcerzak S, Roach R, Taylor S, Rivkin S et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 1998; 16: 890-896.
18. Berenson J, Crowley J, Grogan T, Zangmeister J, Briggs A, Mills G et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163-3168.
19. Shustik C, Belch A, Robinson S, Rubin S, Dolan S, Kovacs M et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute of Canada Clnical Trials Group study: MY7. Proc Amer Soc Clin Oncol 2004; 23: 558.
20. Palumbo A, Boccadoro M, Garino L, Gallone G, Frieri R, Pileri A. Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in relapsed myeloma. Acta Haematol 1993; 90: 71-76.
21. Zervas K, Pouli A, Perifanis V, Papanastasiou K, Chatziyianni M, Mitsouli C et al. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. Eur J Haematol 1996; 57: 142-148.
22. Cohen H, Bartolucci A, Forman W, Silberman H. Consolidation and maintenance therapy in multiple myeloma: Randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol 1986; 4: 888-899.
23. Salmon S, Haut A, Bonnet J, Amare M, Weick J, Durie B et al. Alternating combination chemotherapy and levamisole improve survival in multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1983; 1: 453-461.
24. Stewart K, Chen C, Howson-Jan K, White D, Roy J, Kovacs M et al. A randomized phase II dose-finding trial of thalidomide and prednisone as maintenance therapy for myeloma following autologous stem cell transplant. J Clin Oncol 2002; 21: 269a.
25. Child J, Morgan G, Davied F, Owen R, Bell S, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
26. Segeren C, Sonneveld P, van der Holt B, Vellenga E, Coroockewit A, Verhoef G et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood 2003; 101: 2144-2151.